97 related articles for article (PubMed ID: 8148798)
21. Characterization of the GI transit conditions in Beagle dogs with a telemetric motility capsule.
Koziolek M; Grimm M; Bollmann T; Schäfer KJ; Blattner SM; Lotz R; Boeck G; Weitschies W
Eur J Pharm Biopharm; 2019 Mar; 136():221-230. PubMed ID: 30703546
[TBL] [Abstract][Full Text] [Related]
22. Structure-activity studies on triazolothienodiazepine derivatives as platelet-activating factor antagonists.
Miyazawa S; Okano K; Shimomura N; Clark RS; Kawahara T; Asano O; Yoshimura H; Miyamoto M; Sakuma Y; Muramoto K
Chem Pharm Bull (Tokyo); 1991 Dec; 39(12):3215-20. PubMed ID: 1814614
[TBL] [Abstract][Full Text] [Related]
23. Activity of a novel thienodiazepine derivative as a platelet-activating factor antagonist in guinea pig lungs. Effects on platelet-activating factor and allergen induced eosinophil accumulation.
Tsunoda H; Sakuma Y; Shirato M; Obaishi H; Harada K; Yamada K; Shimomura N; Machida Y; Yamatsu I; Katayama K
Arzneimittelforschung; 1991 Mar; 41(3):224-7. PubMed ID: 1867658
[TBL] [Abstract][Full Text] [Related]
24. Formation of a highly stable complex between BN 50730 [tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4',3'-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4] and the platelet-activating factor receptor in rabbit platelet membranes.
Silva CL; Cruz HN; Violante FA; Cordeiro RS; Martins MA; Noël F
Biochem Pharmacol; 1996 Jan; 51(2):193-6. PubMed ID: 8615889
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.
Brecht HM; Adamus WS; Heuer HO; Birke FW; Kempe ER
Arzneimittelforschung; 1991 Jan; 41(1):51-9. PubMed ID: 1646613
[TBL] [Abstract][Full Text] [Related]
26. Quantitative measurement of BN50727 in human plasma and urine by combined liquid chromatography/negative ion chemical ionization mass spectrometry using a particle beam interface.
Girault J; Malgouyat JM; Lecomte G; Longueville D; Istin B; Fourtillan JB
Biol Mass Spectrom; 1994 Sep; 23(9):581-9. PubMed ID: 7948051
[TBL] [Abstract][Full Text] [Related]
27. Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor.
Walser A; Flynn T; Mason C; Crowley H; Maresca C; Yaremko B; O'Donnell M
J Med Chem; 1991 Mar; 34(3):1209-21. PubMed ID: 2002463
[TBL] [Abstract][Full Text] [Related]
28. Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog.
Kaul S; Shyu WC; Shukla UA; Dandekar KA; Barbhaiya RH
Drug Metab Dispos; 1993; 21(3):447-53. PubMed ID: 8100500
[TBL] [Abstract][Full Text] [Related]
29. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
[TBL] [Abstract][Full Text] [Related]
30. Effects of pentagastrin on intestinal absorption and blood flow in the anaesthetized dog.
Mailman D
J Physiol; 1980 Oct; 307():429-42. PubMed ID: 7205671
[TBL] [Abstract][Full Text] [Related]
31. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation.
Tanaka N; Imai K; Okimoto K; Ueda S; Tokunaga Y; Ibuki R; Higaki K; Kimura T
J Control Release; 2006 May; 112(1):51-6. PubMed ID: 16545477
[TBL] [Abstract][Full Text] [Related]
32. [Biological availability of different oral cimetidine preparations in the dog].
Viernstein H; Plass H; Turnheim K
Arzneimittelforschung; 1990 Jun; 40(6):675-8. PubMed ID: 2397003
[TBL] [Abstract][Full Text] [Related]
33. Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo.
Linn M; Collnot EM; Djuric D; Hempel K; Fabian E; Kolter K; Lehr CM
Eur J Pharm Sci; 2012 Feb; 45(3):336-43. PubMed ID: 22172603
[TBL] [Abstract][Full Text] [Related]
34. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
[TBL] [Abstract][Full Text] [Related]
35. Quantitative measurement of a new synthetic hetrazepine derivative, BN50730, in human plasma and urine by combined liquid chromatography-negative chemical ionization mass spectrometry using a particle beam interface.
Girault J; Malgouyat JM; Longueville D; Lecomte G; Revaud M; Fourtillan JB
J Chromatogr B Biomed Appl; 1994 Aug; 658(2):289-301. PubMed ID: 7820257
[TBL] [Abstract][Full Text] [Related]
36. PAF antagonistic activity of some thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines.
Tahara T; Mikashima H; Terasawa M; Maruyama Y
Chem Pharm Bull (Tokyo); 1987 May; 35(5):2119-21. PubMed ID: 3664818
[No Abstract] [Full Text] [Related]
37. Oral absorption improvement of poorly soluble drug using solid dispersion technique.
Kai T; Akiyama Y; Nomura S; Sato M
Chem Pharm Bull (Tokyo); 1996 Mar; 44(3):568-71. PubMed ID: 8882454
[TBL] [Abstract][Full Text] [Related]
38. Metabolic polymorphism of E6123 in rhesus monkey.
Kusano K; Tanaka S; Ando T; Abe Y; Ida S; Yuzuriha T
Xenobiotica; 1993 Jun; 23(6):599-608. PubMed ID: 8212734
[TBL] [Abstract][Full Text] [Related]
39. Inhibitor effect of apafant on bronchopulmonary responses to platelet activating factor and to antigen in rats.
Akagi M; Nishioka E; Kanoh R; Tachibana M; Fukuishi N
Arzneimittelforschung; 1997 Dec; 47(12):1364-9. PubMed ID: 9450165
[TBL] [Abstract][Full Text] [Related]
40. Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks.
Séchaud R; Dutreix C; Balez S; Pommier F; Dumortier T; Morisson S; Brun E
Int J Clin Pharmacol Ther; 2008 Feb; 46(2):102-8. PubMed ID: 18218291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
